John F. Gilmore Symposium on Nutrition and Small Bowel Disorders
Dr. Rubin discusses the role of diet in managing IBD for the patient and the clinician, as well as evidence that may help differentiate between myth and facts about the impact of diet in IBD.
Characteristics, Comorbidities, and Outcomes of SARS-CoV-2 Infection in Patients with Autoimmune Conditions Treated with Systemic Therapies: a Population-based Study
Dr. Rubin co-authored an original research article describing the relative risk of COVID-19 outcomes among patients with ulcerative colitis, rheumatoid arthritis, or psoriatic arthritis. Click here to read the full article.
Columbia Interventional IBD Symposium: Updates in Medical Management of IBD in 2022
As the number of available therapeutic options and medical interventions for the treatment of inflammatory bowel disease continues to increase, it is necessary to consider how to effectively choose the correct course of action for each patient. In this talk, Dr. Rubin describes how to effectively use medical management as a holistic process to treat inflammatory bowel disease.
Meeting the Needs of Patients With moderate to Severe Ulcerative Colitis: Novel Targets Mean New Opportunities
Although the quantity and quality of options to treat ulcerative colitis (UC) has risen over time, opportunities remain to optimize care for those diagnosed with this highly disruptive disease. Watch Dr. Rubin with colleagues Dr. William Sandborn and Dr. Marla Dubinsky review the impact of UC on quality of life, the limitations of current treatments, and emerging therapeutic options for ulcerative colitis.
Click Here to watch the entire webinar.
Optimal Use of Anti-IL12/23 for the Management of IBD
Dr. Rubin reviews the most recent efficacy and safety data associated with IL-12/23 and IL-23 inhibitors and describes how to position these therapies in personalized therapeutic strategies for IBD.
Click Here to watch the entire webinar.
Empowered Crohn’s Disease Care: Targets, Tools, and Talking to Patients
The treatment of Crohn’s disease (CD) has typically relied on treatment intensification based on patient symptoms, but emerging evidence suggests that a treat-to-target approach may offer important benefits. Dr. Rubin and colleagues Dr. Parambir Dulai and Dr. Corey A. Siegel introduce the benefits of a treat-to-target strategy, how to use clinical decision support tools, and how to employ shared decision making for patient-centered and empowered CD care.
Click Here to watch the entire webinar.
IBDscope – Evolving algorithms for IBD: What Drives choice?
The shared decision making model is a complex network of relationships among the patient, provider, and payer. Dr. Rubin uses an ethical framework to discuss how to take patients’ expectations into account when devising a treatment plan.
Click here to register and watch the entire webinar.
SEQUENCING THERAPIES FOR IBD
With the vast options for IBD therapies in our modern world, which therapy is the right choice? Dr. Rubin discusses a treat to target strategy to monitor disease, optimize treatment, and guide adjustments to the treatment plan.
DE-ESCALATION OF IBD TREATMENT
De-escalation of IBD treatment is an important topic, not only because patients frequently ask when they can stop their therapies, but also in consideration of the costs of therapies, long-term exposures of therapies, and in the chronic management of a condition like Crohn’s disease or ulcerative colitis.
Click here to listen to more about why, when, and how to de-escalate.
CANCER PREVENTION IN IBD
Prevention of cancer in patients with IBD requires understanding the risk factors, educating patients, incorporating regular screenings, and considering the risk in conjunction with the risk of IBD progression.
INFLAMMATORY BOWEL DISEASE FOR RHEUMATOLOGISTS
Dr. Rubin discusses when to suspect IBD in patients with rheumatological conditions, and the relationship among IBD and rheumatology along the gut-synovial axis.
MANAGEMENT OF CROHN’S DISEASE
Dr. Rubin goes over the importance of early diagnosis and effective treatment for patients with Crohn’s Disease, the goals of management, available therapies, the need for monitoring, and how to prevent complications.
HIGH RISK ULCERATIVE COLITIS: WHERE DO WE START?
Dr. Rubin discusses treatment options for patients with high risk ulcerative colitis, the importance of treating aggressively to achieve stable control, how to rule out infections and drug intolerance, and when to discuss surgery.